Pediatric Hematology and Oncology · 2008 · 13 citations · 34 references
MedicineHematologyPediatricsPediatric HematologyPediatric OncologyStem Cell TransplantationAllogeneic Stem Cell TransplantationDonor MatchingHematopoietic Stem Cell TransplantationPediatric LeukemiasTransplant SurvivalAcute Lymphoblastic Leukemia TransplantationMatched Unrelated Donor TransplantationMedian AgeRelated Donor MatchingRelated Donor TransplantationTransplantationTransplantation Outcome AssessmentUnrelated Donation
The authors report the results of 58 children with ALL in 2CR after related (n = 31) or unrelated (n = 27) AHSCT. Characteristics at diagnosis and initial and after relapse antileukemic treatment were similar in the related donor (RD) and the unrelated donor (UD) groups. Conditioning consisted of TBI/CY +/- VP-16 for patients > or = 3 years old (n = 43) and Bu/CY for the rest. Median recipient age was 8 years (range 1-17) in the RD and 9 years (range 3-14) in the UD group. Median follow-up was 54 months (range 24-80) and 52 months (range 22-85) in the RD and the UD groups repectively. The 5-year EFS probability was 43 +/- 9% for the RD group and 36 +/- 9% in the UD group (p = .25). The transplant-related mortality was 16% in the RD and 37% in the UD group (p = .016). In the RD group 36.7% of patients relapsed versus 18.6% in the UD group (p = .05). GvHD associated with organ failure or infection caused most of the transplant-related deaths in both groups. Survivor quality of life for both groups was good (Lansky score < or = 90).
34
Neal Flomenberg · Blood · 2004 · 693 citations · Full text
Mary Eapen, Mary M. Horowitz, John P. Klein et al. · Journal of Clinical Oncology · 2004 · 261 citations · Full text
Medicine, Hematology, Pediatrics +17